tesamorelin & ipamorelin blend and 8mg (6mg / 2mg) acid GHRH analog (Tesamorelin) + synthetic GHS Tesamorelin + Ipamorelin 10mg Blend

Lung Cancer (Amsterdam Netherlands)

Weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) versus CagriSema's 20.4% at 68 weeks (Phase 3 REDEFINE 1), though cross-trial comparisons are limited

When attending an appointment, it may be helpful to: Bring a list of your current medications , including any supplements or over-the-counter products Discuss your weight history and previous treatment attempts , including any prior use of GLP-1 agonists Ask specifically about clinical trial eligibility , as some NHS trusts and academic centres are actively recruiting for obesity-related studies Raise any concerns about online sources offering unlicensed peptides, so your clinician can provide appropriate safety guidance Your GP can refer you to NHS Tier 3 specialist weight management services if you meet the relevant criteria

Thanks, everyone, for all your suggestions and advice